Literature DB >> 17389291

Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.

Jeffrey R Curtis1, Andrew O Westfall, Jeroan Allison, Angela Becker, Mary Elkins Melton, Allison Freeman, Catarina I Kiefe, Marilyn MacArthur, Theresa Ockershausen, Emily Stewart, Norm Weissman, Kenneth G Saag.   

Abstract

BACKGROUND: In light of widespread undertreatment for glucocorticoid-induced osteoporosis (GIOP), we designed a group randomized controlled trial to increase bone mineral density (BMD) testing and osteoporosis medication prescribing among patients receiving long-term glucocorticoid therapy.
METHODS: Using administrative databases of a large US health plan, we identified physicians who prescribed long-term glucocorticoid therapy to at least 3 patients. One hundred fifty-three participating physicians were randomized to receive a 3-module Web-based GIOP intervention or control course. Intervention modules focused on GIOP management and incorporated case-based continuing medical education and personalized audit and feedback of GIOP management compared with that of the top 10% of study physicians. In the year following the intervention, we compared rates of BMD testing and osteoporosis medication prescribing between intervention and control physicians.
RESULTS: Following the intervention, intent-to-treat analyses showed that 78 intervention physicians (472 patients) vs 75 control physicians (477 patients) had similar rates of BMD testing (19% vs 21%, P = .48; rate difference, -2%; 95% confidence interval [CI], -8% to 4%) and osteoporosis medication prescribing (32% vs 29%, P = .34; rate difference, 3%; 95% CI, -3% to 9%). Among 45 physicians completing all modules (343 patients), intervention physicians had numerically but not significantly higher rates of BMD testing (26% vs 16%, P =.04; rate difference, 10%; 95% CI, 1%-20%) and bisphosphonate prescribing (24% vs 17%, P =.09; rate difference, 7%; 95% CI, -1% to 16%) or met a combined end point of BMD testing or osteoporosis medication prescribing (54% vs 44%, P =.07; rate difference, 10%; 95% CI, -1% to 21%) compared with control physicians.
CONCLUSIONS: In the main analysis, a Web-based intervention incorporating performance audit and feedback and case-based continuing medical education had no significant effect on the quality of osteoporosis care. However, dose-response trends showed that physicians with greater exposure to the intervention had higher rates of GIOP management. New cost-effective modalities are needed to improve the quality of osteoporosis care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389291     DOI: 10.1001/archinte.167.6.591

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  41 in total

1.  Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis.

Authors:  Gulsen Ozen; Diane L Kamen; Ted R Mikuls; Bryant R England; Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-11       Impact factor: 4.794

2.  Improving osteoporosis care in high-risk home health patients through a high-intensity intervention.

Authors:  Ryan C Outman; Jeffrey R Curtis; Julie L Locher; Jeroan J Allison; Kenneth G Saag; Meredith L Kilgore
Journal:  Contemp Clin Trials       Date:  2011-10-08       Impact factor: 2.226

3.  Randomized trial to improve fracture prevention in nursing home residents.

Authors:  Cathleen S Colón-Emeric; Kenneth W Lyles; Paul House; Deborah A Levine; Anna P Schenck; Jeroan Allison; Joel Gorospe; Mary Fermazin; Kristi Oliver; Jeffrey R Curtis; Norman Weissman; Aiyuan Xie; Kenneth G Saag
Journal:  Am J Med       Date:  2007-10       Impact factor: 4.965

4.  An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis.

Authors:  L Caplan; A E Hines; E Williams; A V Prochazka; K G Saag; F Cunningham; E Hutt
Journal:  Osteoporos Int       Date:  2010-04-01       Impact factor: 4.507

5.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 6.  Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?

Authors:  Gim Gee Teng; Jeffrey R Curtis; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

Review 7.  Problem-based learning in continuing medical education: review of randomized controlled trials.

Authors:  Hilal Al-Azri; Savithiri Ratnapalan
Journal:  Can Fam Physician       Date:  2014-02       Impact factor: 3.275

Review 8.  Prevention and treatment of bone changes associated with exposure to glucocorticoids.

Authors:  Amy H Warriner; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

9.  Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis.

Authors:  Ege Can Serefoglu; Zafer Tandogdu
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

10.  A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.

Authors:  Monica Ibañez; Ana M Ortiz; Isabel Castrejón; J Alberto García-Vadillo; Inmaculada Carvajal; Santos Castañeda; Isidoro González-Alvaro
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.